decemb
seri
pneumonia
case
unknown
etiolog
emerg
wuhan
central
china
popul
million
peopl
thought
relat
exposur
huanan
seafood
wholesal
market
condit
later
confirm
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
differ
normal
pathogen
viru
power
extend
rapidli
chines
citi
countri
thu
lead
widespread
pneumonia
number
case
sharpli
increas
china
time
outsid
china
number
affect
countri
tripl
consider
alarm
level
spread
sever
world
health
organ
character
pandem
march
pose
great
public
health
clinic
burden
worldwid
epidemiolog
clinic
characterist
patient
report
infect
wide
clinic
spectrum
includ
asymptomat
infect
mild
respiratori
diseas
sever
pneumonia
acut
respiratori
failur
even
death
hematolog
chang
includ
lymphopenia
thrombocytopenia
report
patient
similar
sar
abnorm
coagul
common
complic
manifest
pulmonari
vascular
leakag
intravascular
thrombosi
dissemin
intravascular
coagul
thrombocytopenia
also
common
clinic
manifest
associ
poor
outcom
patient
communityacquir
pneumonia
platelet
contribut
hemostasi
also
particip
inflamm
host
defens
respons
latter
especi
import
lung
infect
although
mani
case
thrombocytopenia
report
patient
sever
viral
pneumonia
thu
suggest
clinic
characterist
associ
baselin
platelet
chang
advers
outcom
remain
unclear
hospitalbas
cohort
studi
conduct
patient
laboratoryconfirm
evalu
associ
platelet
admiss
mortal
particularli
dynam
chang
circul
platelet
role
diseas
progress
retrospect
cohort
studi
conduct
patient
central
hospit
wuhan
januari
follow
march
diagnos
accord
world
health
organ
interim
guidanc
patient
laboratoryconfirm
human
infect
throat
swab
specimen
enrol
malign
tumor
post
craniocerebr
oper
die
admiss
treatment
antiplatelet
drug
transfer
medic
institut
exclud
enrol
patient
follow
discharg
death
requir
inform
consent
waiv
due
urgenc
collect
data
emerg
studi
approv
ethic
committe
central
hospit
wuhan
case
report
form
nurs
record
laboratori
find
radiolog
characterist
review
team
physician
treat
patient
demograph
characterist
gender
age
comorbid
chronic
obstruct
pulmonari
diseas
hypertens
diabet
cardiovascular
diseas
cerebrovascular
diseas
chronic
kidney
diseas
clinic
manifest
laboratori
find
treatment
outcom
dischargedeath
extract
electron
medic
record
laboratori
data
includ
white
blood
cell
count
neutrophil
count
lymphocyt
count
hemoglobin
platelet
count
creactiv
protein
procalcitonin
blood
urea
nitrogen
creatinin
total
bilirubin
alanin
aminotransferas
aspart
aminotransferas
fibrinogen
ddimer
lactat
dehydrogenas
creatin
kinas
arteri
blood
gase
lactat
ratio
collect
admiss
addit
platelet
paramet
includ
plateletcrit
pct
mean
platelet
volum
mpv
fl
platelet
distribut
width
platelet
larger
cell
ratio
plcr
also
gather
accord
test
projectmanu
reagent
instruct
central
hospit
wuhan
normal
refer
interv
platelet
count
therefor
thrombocytopenia
defin
blood
platelet
nonthrombocytopenia
defin
blood
platelet
acut
physiolog
chronic
health
evalu
ii
score
apach
ii
sequenti
organ
failur
assess
criteria
determin
within
h
admiss
data
treatment
measur
includ
antibiot
antiviru
glucocorticoid
intraven
immunoglobulin
therapi
respiratori
support
acquir
hospit
throat
swab
sampl
collect
suspect
patient
admiss
laboratori
confirm
perform
use
realtim
revers
transcriptionpolymeras
chain
reaction
accord
manufactur
protocol
beij
genom
institut
geneodx
biotechnolog
co
ltd
repeat
test
perform
confirm
patient
verifi
viral
clearanc
hospit
discharg
baselin
characterist
continu
categor
variabl
present
median
interquartil
rang
n
respect
examin
u
test
test
fisher
exact
test
appropri
associ
baselin
platelet
paramet
mortal
risk
estim
cox
proport
hazard
regress
model
term
follow
confound
age
sex
baselin
comorbid
includ
chronic
obstruct
pulmonari
diseas
hypertens
diabet
chronic
kidney
diseas
cardiovascular
diseas
cerebrovascular
diseas
glucocorticoid
immunoglobulin
might
affect
hematopoiet
system
treatment
common
clinic
practic
addit
decreas
lymphocyt
count
repres
progress
diseas
creactiv
protein
repres
overal
inflamm
augment
blood
lactat
repres
acut
lung
injuri
tissu
hypoxia
andor
oxygen
debt
associ
mortal
critic
patient
therefor
also
consid
regress
model
smooth
spline
present
associ
baselin
platelet
level
platelet
chang
subsequ
mortal
gener
util
gener
addit
model
surviv
curv
plot
use
method
examin
use
logrank
test
statist
analys
perform
use
r
softwar
r
foundat
http
wwwrprojectorg
version
empowerstat
http
wwwempowerstatscom
x
solut
inc
boston
unless
otherwis
indic
twosid
signific
level
p
use
evalu
statist
signific
among
patient
median
day
rang
day
followup
period
discharg
surviv
die
clinic
characterist
patient
stratifi
admiss
platelet
present
tabl
median
age
year
patient
male
signific
differ
comorbid
observ
patient
thrombocytopenia
nonthrombocytopenia
patient
thrombocytopenia
admiss
like
older
higher
apach
ii
score
nonthrombocytopenia
patient
administ
antibiot
treat
ribavirin
oseltamivir
arbidol
empir
system
glucocorticoid
therapi
intraven
immunoglobulin
use
antiinflammatori
treatment
noninvas
ventil
use
patient
thrombocytopenia
group
higher
proport
noninvas
ventil
therapi
vs
mortal
rate
vs
without
thrombocytopenia
dynam
chang
platelet
count
day
day
onset
diseas
track
determin
major
clinic
featur
observ
progress
compar
nonsurvivor
level
platelet
show
increas
trend
survivor
admiss
p
figur
addit
platelet
neg
associ
apach
ii
score
higher
indic
higher
diseas
sever
admiss
figur
admiss
patient
thrombocytopenia
lower
white
blood
cell
neutrophil
lymphocyt
count
higher
level
procalcitonin
creactiv
protein
compar
without
thrombocytopenia
tabl
remark
differ
found
level
total
bilirubin
aspart
aminotransferas
blood
urea
nitrogen
creatinin
ddimer
indic
significantli
higher
patient
thrombocytopenia
without
thrombocytopenia
decreas
level
observ
thrombocytopenia
group
compar
nonthrombocytopenia
group
analysi
platelet
paramet
reveal
patient
thrombocytopenia
lower
level
platelet
pct
higher
level
mpv
plcr
without
thrombocytopenia
cox
proport
hazard
regress
model
adjust
sever
deathrel
risk
factor
admiss
includ
age
sex
baselin
comorbid
lymphocyt
count
blood
lactat
creactiv
protein
glucocorticoid
therapi
intraven
immunoglobulin
result
reveal
adjust
potenti
confound
platelet
pct
independ
risk
mortal
tabl
ii
analys
per
increment
platelet
count
significantli
associ
decreas
mortal
hr
ci
patient
tabl
iii
analysi
patient
platelet
count
associ
still
robust
smooth
spline
plot
visual
present
nonlinear
relationship
platelet
admiss
mortal
observ
mortal
decreas
elev
platelet
count
curv
gradual
tend
gentl
platelet
count
figur
continu
track
chang
platelet
within
first
day
admiss
reveal
platelet
increas
risk
death
decreas
treatment
viceversa
figur
analysi
show
worst
outcom
note
subgroup
patient
platelet
level
admiss
decreas
day
follow
patient
platelet
level
admiss
increas
day
patient
platelet
level
admiss
decreas
day
patient
platelet
level
admiss
increas
day
figur
patient
usual
rapid
progress
pneumon
even
develop
ard
death
among
patient
enrol
admit
platelet
normal
rang
thrombocytopenia
although
major
current
studi
reveal
decreas
number
platelet
group
sever
research
investig
dynam
chang
platelet
estim
associ
baselin
platelet
platelet
chang
subsequ
mortal
patient
infect
present
studi
clinic
characterist
compar
patient
without
thrombocytopenia
cox
proport
hazard
regress
analysi
use
adjust
sever
deathrel
risk
factor
admiss
studi
highlight
follow
thrombocytopenia
admiss
associ
mortal
almost
three
time
higher
patient
without
thrombocytopenia
b
platelet
count
independ
risk
factor
mortal
c
dynam
chang
platelet
close
relat
death
treatment
studi
highlight
platelet
monitor
might
import
prognosi
enhanc
platelet
activ
lead
platelet
deposit
damag
pulmonari
blood
vessel
support
variou
clinic
studi
thrombocytopenia
import
featur
sar
thrombocytopenia
exceed
incid
rate
patient
sar
import
indic
poor
prognosi
metaanalysi
patient
report
thrombocytopenia
associ
threefoldenhanc
risk
sever
lower
platelet
count
observ
mortal
similar
studi
current
work
confirm
thrombocytopenia
admiss
associ
death
patient
platelet
patient
sar
neg
correl
level
involv
adhes
chemotaxi
contribut
earli
vascular
injuri
suppress
cell
function
vascular
injuri
immunosuppress
may
explain
poor
outcom
use
cox
regress
model
multivari
analysi
found
platelet
pct
independ
risk
factor
predict
death
although
platelet
routin
measur
daili
role
platelet
pct
predict
outcom
patient
previous
report
correl
platelet
dynam
diseas
prognosi
studi
differ
platelet
threshold
use
epidemiolog
studi
incid
risk
factor
consequ
thrombocytopenia
among
critic
ill
patient
cohort
nonlinear
relationship
platelet
admiss
mortal
observ
trend
tend
gentl
platelet
count
figur
analysi
show
patient
platelet
level
admiss
decreas
day
highest
mortal
rate
wherea
platelet
level
admiss
increas
day
lowest
mortal
rate
moreov
thrombocytopenia
close
relationship
prognosi
even
within
normal
refer
rang
dynam
chang
platelet
within
first
day
admiss
neg
correl
prognosi
cox
proport
hazard
regress
model
display
decreas
mortal
risk
everi
increas
platelet
summari
platelet
count
import
prognost
marker
patient
dynam
level
platelet
treatment
close
associ
death
pct
calcul
platelet
count
level
admiss
still
retain
detriment
effect
clinic
outcom
mechan
thrombocytopenia
poorli
understood
sever
potenti
explan
consid
histolog
examin
lung
necropsi
patient
reveal
bilater
diffus
alveolar
damag
cellular
fibromyxoid
exud
interstiti
mononuclear
inflammatori
infiltr
domin
lymphocyt
find
rais
possibl
immunopatholog
damag
lung
tissu
damag
lung
tissu
would
caus
platelet
activ
aggreg
lung
thrombi
format
site
injuri
may
lead
consumpt
platelet
megakaryocyt
addit
induc
lowgrad
dissemin
intravascular
coagulopathi
state
character
elev
ddimer
fibrinogen
increas
consumpt
platelet
damag
lung
lung
may
site
platelet
releas
matur
megakaryocyt
inflamm
longterm
oxygen
treatment
also
result
extens
alveolar
damag
pulmonari
patholog
chang
pulmonari
capillari
bed
morpholog
alter
thu
affect
lung
megakaryocyt
fragment
megakaryocytopoiesi
increas
consumpt
decreas
product
platelet
may
affect
thrombocytopenia
similar
sar
coronaviru
thrombocytopenia
may
involv
mechan
new
condit
may
directli
infect
hematopoiet
precursor
cell
inhibit
growth
cd
express
human
bone
marrow
cell
may
induc
growth
inhibit
bind
hematopoiet
cell
bone
marrow
stromal
cell
result
abnorm
hematopoiesi
immunodefici
bodi
undergo
immunemedi
hematopoiet
stem
cell
damag
therebi
lead
thrombocytopenia
studi
subject
sever
limit
first
observ
studi
conclud
report
associ
platelet
paramet
mortal
causal
second
exclud
possibl
remain
residu
confound
unmeasur
potenti
confound
third
patholog
mechan
platelet
paramet
progress
remain
poorli
defin
clinic
basic
research
necessari
clarifi
issu
although
studi
first
identifi
associ
platelet
paramet
mortal
risk
patient
largescal
multicent
studi
warrant
confirm
find
hospitalbas
cohort
studi
among
confirm
patient
reveal
associ
baselin
platelet
platelet
chang
subsequ
mortal
henc
monitor
platelet
hospit
may
import
prognosi
patient
